DNA damage repair gene mutations predict the efficacy of platinum-based chemotherapy and immunotherapy plus platinum-based chemotherapy in advanced non-small cell lung cancer: a retrospective Chinese cohort study

BACKGROUND: Platinum-based chemotherapy (PC) and immunotherapy plus platinum-based chemotherapy (IPC) remain the first-line treatment for advanced NSCLC. But only a minority patients benefit from PC, and existing biomarkers, such as PD-L1, have been shown to be defective in predicting the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Zhiwei, Sun, Lingling, Zheng, Yating, Chen, Hanrui, Zheng, Xinting, Luo, Jiamin, Gu, Chuying, Lin, Ruiting, Huang, Mengli, Bai, Yuezong, Chen, Zhe-Sheng, Kinslow, Connor J., Loh, Jerold, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830265/
https://www.ncbi.nlm.nih.gov/pubmed/36636408
http://dx.doi.org/10.21037/tlcr-22-746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830265/
https://www.ncbi.nlm.nih.gov/pubmed/36636408
http://dx.doi.org/10.21037/tlcr-22-746

Ejemplares similares